Gilead Sciences’ Kite Makes $350M Gene Therapy Gamble — Meet Interius Biotherapeutics!

Gilead Sciences has had a monumental few months, delivering one of its most successful quarters in recent history. The Q2 2025 earnings call underscored the strength of Gilead’s HIV franchise—buoyed by the FDA approval and early launch of Yeztugo (lenacapavir) for twice-yearly PrEP, the rising momentum in oncology (notably with Trodelvy), and a growing footprint in cell therapy. But beneath the surface of this commercial momentum, a strategic pivot may be underway: Gilead is reportedly in advanced talks to acquire Interius BioTherapeutics. While the company hasn’t commented publicly, the move suggests Gilead is looking to deepen its R&D portfolio in in vivo cell and gene therapy, with potential applicability across oncology and immunology. As Gilead faces mounting pressure to sustain growth beyond 2030 amid looming patent cliffs, acquiring Interius could potentially unlock scientific synergies and add transformative platform capabilities. But what does Interius bring to the table, and how could this acquisition reshape Gilead’s future?